Alendronic acid/guanidine dextran conjugate - DexTech Medical AB
Alternative Names: Alendronate/dextran/guanidine; OsteodexLatest Information Update: 16 Aug 2022
At a glance
- Originator DexTech Medical
- Class Antihypercalcaemics; Antineoplastics; Antithrombotics; Bisphosphonates; Calcium regulators; Drug conjugates; Glucans; Plasma expanders; Small molecules
- Mechanism of Action Adrenergic receptor agonists; Osteoclast inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Bone metastases
- Phase I/II Multiple myeloma
Most Recent Events
- 10 Aug 2022 Phase-I/II clinical trials in Multiple myeloma (In adults, In the elderly, Refractory metastatic disease) in Sweden (IV) (EudraCT2022-001635-91)
- 29 Jun 2016 Discontinued - Phase-II for Bone metastases in Denmark (IV) (NCT02378870)
- 31 May 2016 DexTech Medical initiates a phase-II clinical trials in Bone metastases in Sweden, Finland, Latvia, Estonia (IV) (NCT02825628)